Aubex’s R&D program shows promise, particularly in cancers where fibrosis drives progression, such as HER2+ and triple-negative (TN) breast cancers, pancreatic cancer, esophageal squamous cell carcinoma (SCC), colon cancer, and non-small cell lung cancer. These solid tumors are notable for their pronounced fibrotic response, which impedes effective immune responses.

Jeffrey A. Glazer expressed his excitement about the company’s mission, stating, “Aubex Therapeutics is thrilled to launch with a unique R&D program addressing the TME. This innovative program demonstrates promising early activity in altering the tumor microenvironment, marking a significant milestone in immuno-oncology. We are eager to lead the way in developing therapies that hold the potential to dramatically improve outcomes for cancer patients by reducing fibrosis and boosting a patient’s immune response.”

The launch of Aubex Therapeutics marks a pivotal moment in the ongoing effort to develop more effective cancer treatments. With a focus on achieving groundbreaking progress in the therapy of solid tumors, Aubex is dedicated to improving patient outcomes through innovative research.

About Aubex Therapeutics Inc.

Headquartered in San Diego, CA, Aubex Therapeutics, Inc. is a biotechnology leader dedicated to advancing oncology treatment. Guided by industry veterans, Aubex focuses on novel therapies that improve the dynamics of the tumor microenvironment. Committed to innovation, patient well-being, and ethical practices, the company strives to enhance treatment efficacy and patient quality of life.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423475058/en/